Cognition Therapeutics Presents Proteomic Biomarker Data Demonstrating Prominent Effects of CT1812 in Altering Underlying Alzheimer's Disease ProcessesGlobeNewsWire • 03/28/23
Cognition Therapeutics Reports Year End 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 03/23/23
Cognition Therapeutics to Present Proteomic Biomarker Analyses from Clinical Studies of CT1812 in Patients with Alzheimer's Disease at AD/PD 2023GlobeNewsWire • 03/21/23
UPDATE – Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 ResultsGlobeNewsWire • 03/16/23
Cognition Therapeutics Announces Development Plans for Oral CT1812 in Geographic Atrophy Secondary to Dry AMDGlobeNewsWire • 03/15/23
Cognition Therapeutics to Present at the 33rd Annual Oppenheimer & Co Annual Healthcare ConferenceGlobeNewsWire • 03/07/23
Cognition Therapeutics Announces New Episode of “Conversations” Podcast: What if it's not Alzheimer's? The Caregiver's Perspective on Lewy Body DementiaGlobeNewsWire • 02/21/23
Cognition Therapeutics Completes Enrollment of CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer's DiseaseGlobeNewsWire • 02/09/23
These 10 Stocks Had the Most Insider Buying Activity During the December Quarter24/7 Wall Street • 01/10/23
Cognition Therapeutics Announces New “Conversations” Podcast Episode on Key Insights from Recent Clinical Trials in Alzheimer's DiseaseGlobeNewsWire • 12/22/22
Cognition Therapeutics Announces Participation in Sachs 6th Annual Neuroscience Forum, Biotech Showcase, and BIO Partnering @ JPM During "J.P. Morgan Week 2023"GlobeNewsWire • 12/21/22
First Participant Dosed in Europe as Cognition Therapeutics Expand Phase 2 Alzheimer's Disease Clinical Trial of Oral CT1812GlobeNewsWire • 12/15/22
Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMDGlobeNewsWire • 12/01/22
Cognition Therapeutics Launches Neuroscience Thought Leader Conversations Podcast/Webinar SeriesGlobeNewsWire • 11/21/22
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 11/14/22
Cognition Therapeutics is Recruiting for Lewy Body Dementia Phase 2 SHIMMER Trial in Seventeen Research Sites Across the U.S.GlobeNewsWire • 10/12/22
Cognition Therapeutics Appoints CNS Drug Development Expert to VP Clinical DevelopmentGlobeNewsWire • 10/11/22
Cognition Therapeutics to Participate in the 2022 Cantor Fitzgerald Neurology & Psychiatry ConferenceGlobeNewsWire • 09/29/22
Cognition Therapeutics Awarded $2.14 Million in Supplemental Grant Funding from NIA to Support SEQUEL Clinical TrialGlobeNewsWire • 09/27/22
Cognition Therapeutics Announces Participation in September Investment ConferencesGlobeNewsWire • 09/06/22
Cognition Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 08/09/22